Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473034 | 0.79 | RAB9A (0.50) | ERCC5FEN1SLC6A1NPC1RAB9A | |
| SCHEMBL7925207 | 0.74 | NPC1 (0.42) | ERCC5FEN1SLC6A1NPC1RAB9A | |
| SCHEMBL6548199 | 0.74 | NPC1 (0.42) | ERCC5FEN1SLC6A1NPC1RAB9A | |
| SCHEMBL9364531 | 0.72 | ERCC5 (0.52) | ERCC5FEN1NPC1RAB9AHPGD | |
| SCHEMBL10285292 | 0.72 | L3MBTL1 (0.55) | NPC1RAB9AHPGDALDH1A1KMT2A | |
| SCHEMBL3881991 | 0.69 | HPGD (0.46) | SLC6A1NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL29402362 | 0.68 | AKR1C3 (0.61) | ERCC5FEN1NPC1RAB9AKCNK3 | |
| Benzene SCHEMBL27600962 | 0.68 | AKR1C3 (0.61) | ERCC5FEN1NPC1RAB9AKCNK3 | |
| SCHEMBL9451511 | 0.68 | AKR1C3 (0.61) | ERCC5FEN1NPC1RAB9AKCNK3 | |
| SCHEMBL4711341 | 0.68 | NPC1 (0.43) | ERCC5FEN1NPC1RAB9AKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872401-B2 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | L'OREAL (FR) | 2005-03-29 | — | — | US | claimed |
| US-20040009200-A1 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | SOCIETE L'OREAL S.A. (FR) | 2004-01-15 | — | — | US | claimed |
| EP-1545548-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA Pharma AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| US-6872401-B2 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | L'OREAL (FR) | 2005-03-29 | — | — | US | disclosed |
| WO-2004019955-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| US-20040009200-A1 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | SOCIETE L'OREAL S.A. (FR) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009200-A1 | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil | KRT18, DHCR24, FABP4 | ERCC5 26/4885FEN1 2628/4885SLC6A1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.